Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Trevi Therapeutics Inc is a biotechnology business based in the US. Trevi Therapeutics shares (TRVI) are listed on the NASDAQ and all prices are listed in US Dollars. Trevi Therapeutics employs 23 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$1.33|
|52-week range||$1.10 - $3.98|
|50-day moving average||$1.36|
|200-day moving average||$1.92|
|Wall St. target price||$10.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.84|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-20)||4.72%|
|1 month (2021-09-27)||-11.33%|
|3 months (2021-07-27)||-29.26%|
|6 months (2021-04-27)||-44.12%|
|1 year (2020-10-27)||-59.82%|
|2 years (2019-10-25)||-63.76%|
|3 years (2018-10-23)||N/A|
|5 years (2016-10-23)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-48.88%|
|Return on equity TTM||-121.39%|
|Market capitalisation||$31.5 million|
TTM: trailing 12 months
There are currently 110,965 Trevi Therapeutics shares held short by investors – that's known as Trevi Therapeutics's "short interest". This figure is 26% up from 88,043 last month.
There are a few different ways that this level of interest in shorting Trevi Therapeutics shares can be evaluated.
Trevi Therapeutics's "short interest ratio" (SIR) is the quantity of Trevi Therapeutics shares currently shorted divided by the average quantity of Trevi Therapeutics shares traded daily (recently around 80409.420289855). Trevi Therapeutics's SIR currently stands at 1.38. In other words for every 100,000 Trevi Therapeutics shares traded daily on the market, roughly 1380 shares are currently held short.
However Trevi Therapeutics's short interest can also be evaluated against the total number of Trevi Therapeutics shares, or, against the total number of tradable Trevi Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Trevi Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Trevi Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.027% of the tradable shares (for every 100,000 tradable Trevi Therapeutics shares, roughly 27 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Trevi Therapeutics.
Find out more about how you can short Trevi Therapeutics stock.
We're not expecting Trevi Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Trevi Therapeutics's shares have ranged in value from as little as $1.1 up to $3.975. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Trevi Therapeutics's is 0.021. This would suggest that Trevi Therapeutics's shares are less volatile than average (for this exchange).
Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease, as well as to treat chronic kidney disease-associated with pruritus. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation; and Rutgers to develop and commercialize products incorporating nalbuphine for any human or animal use. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.